|
| Status |
Public on Sep 27, 2024 |
| Title |
Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Deferasirox (DFX) can improve erythropoiesis in patients with MDS. We sought to test how these changes occur and whether myelopoiesis broadly is affected by analyzing neutrophils and neutrophil precursors treated with DFX.
|
| |
|
| Overall design |
We cultured human, LIN- bone marrow and peripheral blood cells in media containing GCSF for 5 days while treating with either DMSO, 1.5 uM DFX, or 3 uM DFX.
|
| |
|
| Contributor(s) |
Jeffries NE, Chetal K, Sadreyev RI, Sykes DB |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Aug 15, 2024 |
| Last update date |
Sep 28, 2024 |
| Contact name |
Nathan Elias Jeffries |
| E-mail(s) |
njeffries@mgh.harvard.edu
|
| Organization name |
Massachusetts General Hospital
|
| Department |
CRM
|
| Lab |
David B Sykes
|
| Street address |
185 Cambridge St MCPZN 4400
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02114 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (4)
|
|
| Relations |
| BioProject |
PRJNA1148639 |
Less...
More...